Management of difficult clinical situations in rheumatoid arthritis: hepatitis;Tratamiento de situaciones clínicas difíciles en pacientes que presentan artritis reumatoide con hepatitis

Reumatologia Clinica

Volumn 5, Issue SUPPL. 1, 2009, Pages 53-60

  Ibáñez Bosch, Rosario ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Anti TNF; Hepatitis B; Hepatitis C; Hepatitis reactivation; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CROHN DISEASE; DRUG CONTRAINDICATION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER FAILURE; LIVER TOXICITY; RHEUMATOID ARTHRITIS; SIDE EFFECT; VIRUS REACTIVATION; VIRUS REPLICATION; CHRONIC HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; VIRUS HEPATITIS;

EID: 64749110142     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2008.11.006     Document Type: Article

References (42)

1. Farah M., Al Rashidi A., Owen Da., Yoshida E.M., and Reid G.D. Granulomatous hepatitis associated with Etanercept therapy. J Rheumatol 35 (2008) 349-351
2. Ozorio G., McGarity B., Bak H., Jordan A.S., Lau H., and Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 187 (2007) 524-526
3. Calabrese L.H., Zein N., and Vassipoulos D. Safety of anti-tumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis 63 supp II (2004) ii18-ii24
4. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frecuency of hepatitis B reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299-307
5. Hsieh C.Y., Huang H.H., Lin C.H., Chung L.W., Liao Y.M., Bai L.Y., et al. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B cell lymphoma. J Clin Oncol 26 15 (2008) 2584-2586
6. Yeo W., Chan P., Ho W., Zee B., Lam K., Lei K., et al. Lamivudine for prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 5 (2004) 927-934
7. Firpi R.J., and Nelson D.R. Management of viral hepatitis in hematologic malignancies. Blood Rev 22 (2008) 117-126
8. He Y.F., Wang F.H., Jiang W.Q., Xu R.H., Sun X.F., Xia Z.J., et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab containing regimens for lymphoma. Ann Hematol 87 (2008) 481-485
9. Hui C.K., Chueng W.W., Au W.Y., Lie A.K., Zhang H.Y., Yueng Y.H., et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54 (2005) 1597-1603
10. Calabrese L.H., Zein N., and Vassipoulos D. Hepatitis B virus (HBV) reactivation with immunosupressive therapy in rheumatic diseases: Assessment and preventive strategies. Ann Rheum Dis 65 (2006) 983-989
11. Carroll M.B., and Bond M.I. Use of tumor necrosis factor α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum (2008) 10.1016/j.semarthrit.2007.10.011
12. Narváez J., and Rodriguez Moreno J. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 25 (1998) 2037-2038
13. Flowers M.A., Healthcote J., Wanless I.R., Sherman M., Reynolds Wj., Cameron R.G., et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low doses methotrexate therapy. Ann Intern Med 112 (1990) 381-382
14. Gwak G.Y., Koh K.C., and Kim H.Y. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 25 6 (2007) 888-889
15. Bellisai F., Gianitti C., Donvito A., and Galeazi M. Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumat 26 (2007) 1127-1129
16. Wendling D., Auge B., Bettinger D., Lohse A., Le Huede G., Bresson-Hadni S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005) 788-789
17. Ojiro K., Naganuma M., Ebinuma H., Kunimoto H., Tada S., Ogata H., et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 43 5 (2008) 397-401
18. Ito S., Nakazono K., Murasawa A., Mita Y., Hata K., Saito N., et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 41 (2001) 339-342
19. Roux C.H., Brocq O., Breuil V., Albert C., and Euller-Ziegler L. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45 (2006) 1294-1297
20. Ostuni P., Botsios C., Punzi L., Sfriso P., and Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid artritis treated with low infliximab dose methotrexate. Ann Rheum Dis 65 (2003) 686-687
21. Michel M., Duvoux C., Hezode C., and Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still's disease. J Rheumatol 30 (2003) 1624-1625
22. Ferri C., Ferraccioli G., Ferrari D., Galeazzi M., Lapadula G., Montecucco C., et al. Safety of anti-tumor necrosis factor -α therapy in patients with rheumatoid arthritis and crhonic hepatitis B virus infection. J Rheumatol 35 (2008) 10 [Epub ahead of print. J Rheumatol First release 1 aug 2008]
23. Raftery G., Griffiths B., Kav L., and Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology 45 10 (2006) 1294-1297
24. Raftery G., Griffiths B., Kay L., and Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology 46 8 (2007) 1382
25. Esteve M., Saro C., Gonzalez-Huix F., Suárez F., Forné M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Chron's disease patients: Needs for primary prophylaxis. Gut 53 (2004) 1363-1365
26. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J.M., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
27. Benucci M., Manfredi M., and Mecocci L. Effect of etanercept pus lamivudine in a patients with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 14 (2008) 245-246
28. Cansu D., Kalifoglu T., and Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35 (2008) 421-424
29. Madonia S., Orlando O., Scimeca D., Olivo M., Rossi F., and Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 13 (2007) 508-509
30. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: Need for HBV- screening?. World J Gastroenterol 12 (2006) 974-976
31. Parke F., and Reveille J. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 5 (2004) 800-804
32. De Simone C., Paradisi A., Capizzi R., Carbone A., Siciliano M., Amerio P.L., et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 54 (2006) 1102-1104
33. Rokbsar C., Rabban N., and Coben S. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis and concomitant hepatitis C. J Am Acad Dermatol 54 (2006) 361-362
34. Linardaki G., Katsarou O., Ioannidou P., Karafoulidou A., and Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 3 (2007) 1353-1355
35. Marotte H., Fontanges E., Bailly F., Zoullim F., Trepo C., and Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 46 (2007) 97-99
36. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumor necrosis factor α antagonist on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
37. Vauloup C., Krzysiek R., Greangeot Keros L., Wendling D., Goupille P., Brault R., et al. Effects of tumor necrosis factor antagonist on hepatitis C- related immunological abnormalities. Eur Cytokine Netw 17 (2006) 290-293
38. Zein N., and for the Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavarin in treatment-naive patients with crhonic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
39. Han S.H.B. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 66 (2006) 1831-1851
40. Antonelli A., Ferri C., Galeazzi M., Giannitti C., Manno D., Mieli-Vergani G., et al. HCV infection: Pathogenesis, clinical manifestations and therapy. Clin Exp Rheum 26 suppl 48 (2008) S39-S48
41. Nathan D.M., Angus P.W., and Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach. J Gastroenterol and Hepatol 21 (2006) 1366-1371
42. Shibolet O., Ilan Y., Gillis S., Hubert A., Shouval D., and Safadi R. Lamivudine therapy for prevention of immunosuppressive induced hepatitis B virus reactivation in hepatitis B surface antigens carriers. Blood 100 (2002) 391-396